Literature DB >> 27654338

A Multilaboratory, Multicountry Study To Determine MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing of Selected First-Line Antituberculosis Drugs, Second-Line Injectables, Fluoroquinolones, Clofazimine, and Linezolid.

Koné Kaniga1, Daniela M Cirillo2, Sven Hoffner3, Nazir A Ismail4,5, Devinder Kaur6, Nacer Lounis7, Beverly Metchock8, Gaby E Pfyffer9, Amour Venter10.   

Abstract

Our objective was to establish reference MIC quality control (QC) ranges for drug susceptibility testing of antimycobacterials, including first-line agents, second-line injectables, fluoroquinolones, and World Health Organization category 5 drugs for multidrug-resistant tuberculosis using a 7H9 broth microdilution MIC method. A tier-2 reproducibility study was conducted in eight participating laboratories using Clinical Laboratory and Standards Institute (CLSI) guidelines. Three lots of custom-made frozen 96-well polystyrene microtiter plates were used and prepared with 2× prediluted drugs in 7H9 broth-oleic acid albumin dextrose catalase. The QC reference strain was Mycobacterium tuberculosis H37Rv. MIC frequency, mode, and geometric mean were calculated for each drug. QC ranges were derived based on predefined, strict CLSI criteria. Any data lying outside CLSI criteria resulted in exclusion of the entire laboratory data set. Data from one laboratory were excluded due to higher MIC values than other laboratories. QC ranges were established for 11 drugs: isoniazid (0.03 to 0.12 μg/ml), rifampin (0.03 to 0.25 μg/ml), ethambutol (0.25 to 2 μg/ml), levofloxacin (0.12 to 1 μg/ml), moxifloxacin (0.06 to 0.5 μg/ml), ofloxacin (0.25 to 2 μg/ml), amikacin (0.25 to 2 μg/ml), kanamycin (0.25 to 2 μg/ml), capreomycin (0.5 to 4 μg/ml), linezolid (0.25 to 2 μg/ml), and clofazimine (0.03 to 0.25 μg/ml). QC ranges could not be established for nicotinamide (pyrazinamide surrogate), prothionamide, or ethionamide, which were assay nonperformers. Using strict CLSI criteria, QC ranges against the M. tuberculosis H37Rv reference strain were established for the majority of commonly used antituberculosis drugs, with a convenient 7H9 broth microdilution MIC method suitable for use in resource-limited settings.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27654338      PMCID: PMC5121386          DOI: 10.1128/JCM.01138-16

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  A new rapid and simple colorimetric method to detect pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide.

Authors:  Anandi Martin; Howard Takiff; Peter Vandamme; Jean Swings; Juan Carlos Palomino; Françoise Portaels
Journal:  J Antimicrob Chemother       Date:  2006-06-02       Impact factor: 5.790

Review 2.  Setting and revising antibacterial susceptibility breakpoints.

Authors:  John Turnidge; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

3.  Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells.

Authors:  A Pascual; I García; S Ballesta; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

4.  New susceptibility breakpoints and the regional variability of MIC distribution in Mycobacterium tuberculosis isolates.

Authors:  Jotam Pasipanodya; Shashikant Srivastava; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2012-10       Impact factor: 5.191

5.  Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium.

Authors:  Devyani Deshpande; Shashikant Srivastava; Claudia Meek; Richard Leff; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

6.  Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections.

Authors:  P Juréen; K Angeby; E Sturegård; E Chryssanthou; C G Giske; J Werngren; M Nordvall; A Johansson; G Kahlmeter; S Hoffner; T Schön
Journal:  J Clin Microbiol       Date:  2010-03-17       Impact factor: 5.948

7.  A Multilaboratory, Multicountry Study To Determine Bedaquiline MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing.

Authors:  Koné Kaniga; Daniela M Cirillo; Sven Hoffner; Nazir A Ismail; Devinder Kaur; Nacer Lounis; Beverly Metchock; Gaby E Pfyffer; Amour Venter
Journal:  J Clin Microbiol       Date:  2016-09-21       Impact factor: 5.948

8.  Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis.

Authors:  Thomas Schön; Pontus Juréen; Christian G Giske; Erja Chryssanthou; Erik Sturegård; Jim Werngren; Gunnar Kahlmeter; Sven E Hoffner; Kristian A Angeby
Journal:  J Antimicrob Chemother       Date:  2009-07-23       Impact factor: 5.790

9.  Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis.

Authors:  Kristian Ängeby; Pontus Juréen; Gunnar Kahlmeter; Sven E Hoffner; Thomas Schön
Journal:  Bull World Health Organ       Date:  2012-05-29       Impact factor: 9.408

10.  Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis.

Authors:  Emmanuel Chigutsa; Sandra Meredith; Lubbe Wiesner; Nesri Padayatchi; Joe Harding; Prashini Moodley; William R Mac Kenzie; Marc Weiner; Helen McIlleron; Carl M J Kirkpatrick
Journal:  Antimicrob Agents Chemother       Date:  2012-05-07       Impact factor: 5.191

View more
  13 in total

1.  1,4-Benzoquinone antimicrobial agents against Staphylococcus aureus and Mycobacterium tuberculosis derived from scorpion venom.

Authors:  Edson Norberto Carcamo-Noriega; Shyam Sathyamoorthi; Shibdas Banerjee; Elumalai Gnanamani; Monserrat Mendoza-Trujillo; Dulce Mata-Espinosa; Rogelio Hernández-Pando; José Ignacio Veytia-Bucheli; Lourival D Possani; Richard N Zare
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-10       Impact factor: 11.205

2.  Standards for MIC testing that apply to the majority of bacterial pathogens should also be enforced for Mycobacterium tuberculosis complex.

Authors:  T Schön; E Matuschek; S Mohamed; M Utukuri; S Heysell; J-W Alffenaar; S Shin; E Martinez; V Sintchenko; F P Maurer; P M Keller; G Kahlmeter; C U Köser
Journal:  Clin Microbiol Infect       Date:  2019-02-14       Impact factor: 8.067

3.  Mutation detection and minimum inhibitory concentration determination against linezolid and clofazimine in confirmed XDR-TB clinical isolates.

Authors:  Kamal Singh; Swati Sharma; Tuhina Banerjee; Ankush Gupta; Shampa Anupurba
Journal:  BMC Microbiol       Date:  2022-10-03       Impact factor: 4.465

4.  Prediction of drug resistance profile of multidrug-resistant Mycobacterium tuberculosis (MDR-MTB) isolates from newly diagnosed case by whole genome sequencing (WGS): a study from a high tuberculosis burden country.

Authors:  Wenwen Sun; Xuwei Gui; Zheyuan Wu; Yangyi Zhang; Liping Yan
Journal:  BMC Infect Dis       Date:  2022-05-27       Impact factor: 3.667

5.  Non-commercial phenotypic assays for the detection of Mycobacterium tuberculosis drug resistance: a systematic review.

Authors:  Irina Kontsevaya; Jim Werngren; Yen Holicka; Kadri Klaos; Anh Tran; Vladyslav Nikolayevskyy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-10-30       Impact factor: 3.267

6.  Ethambutol Partitioning in Tuberculous Pulmonary Lesions Explains Its Clinical Efficacy.

Authors:  Matthew Zimmerman; Jodi Lestner; Brendan Prideaux; Paul O'Brien; Isabela Dias-Freedman; Chao Chen; Jillian Dietzold; Isaac Daudelin; Firat Kaya; Landry Blanc; Pei-Yu Chen; Steven Park; Padmini Salgame; Jansy Sarathy; Véronique Dartois
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

7.  Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis.

Authors:  Paola M V Rancoita; Federica Cugnata; Ana Luíza Gibertoni Cruz; Philip W Fowler; Daniela M Cirillo; Emanuele Borroni; Sarah J Hoosdally; Timothy M Walker; Clara Grazian; Timothy J Davies; Timothy E A Peto; Derrick W Crook
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

8.  Whole-Transcriptome and -Genome Analysis of Extensively Drug-Resistant Mycobacterium tuberculosis Clinical Isolates Identifies Downregulation of ethA as a Mechanism of Ethionamide Resistance.

Authors:  Lynne de Welzen; Vegard Eldholm; Kashmeel Maharaj; Abigail L Manson; Ashlee M Earl; Alexander S Pym
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

9.  Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study.

Authors:  Lina Davies Forsman; Katarina Niward; Yi Hu; Rongrong Zheng; Xubin Zheng; Ran Ke; Weiping Cai; Chao Hong; Yang Li; Yazhou Gao; Jim Werngren; Jakob Paues; Johanna Kuhlin; Ulrika S H Simonsson; Erik Eliasson; Jan-Willem Alffenaar; Mikael Mansjö; Sven Hoffner; Biao Xu; Thomas Schön; Judith Bruchfeld
Journal:  BMJ Open       Date:  2018-10-04       Impact factor: 2.692

10.  Validation of Bedaquiline Phenotypic Drug Susceptibility Testing Methods and Breakpoints: a Multilaboratory, Multicountry Study.

Authors:  Koné Kaniga; Akio Aono; Emanuele Borroni; Daniela Maria Cirillo; Christel Desmaretz; Rumina Hasan; Lavania Joseph; Satoshi Mitarai; Sadia Shakoor; Gabriela Torrea; Nazir Ahmed Ismail; Shaheed V Omar
Journal:  J Clin Microbiol       Date:  2020-03-25       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.